This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
One task, one interaction, one pair, experts advocate
The endorsement follows overwhelming support for the share swap preceding the merger,
Subscribe To Our Newsletter & Stay Updated
